Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SRP-4045 and SRP-4053 in Duchenne Muscular Dystrophy
2015-002069-52Phase 3Unknown
- Sponsor
- Sarepta Therapeutics
- Start
- Sep 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of casimersen and golodirsen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Sarepta Therapeutics. Primary endpoint: Change from Baseline at Week 96 in 6-minute walk test (6MWT). Status: unknown.
02
Drugs
casimersengolodirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2015-002069-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002069-52.